Cell Death and Disease (Jan 2021)

The necroptotic cell death pathway operates in megakaryocytes, but not in platelet synthesis

  • Diane Moujalled,
  • Pradnya Gangatirkar,
  • Maria Kauppi,
  • Jason Corbin,
  • Marion Lebois,
  • James M. Murphy,
  • Najoua Lalaoui,
  • Joanne M. Hildebrand,
  • John Silke,
  • Warren S. Alexander,
  • Emma C. Josefsson

DOI
https://doi.org/10.1038/s41419-021-03418-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Necroptosis is a pro-inflammatory cell death program executed by the terminal effector, mixed lineage kinase domain-like (MLKL). Previous studies suggested a role for the necroptotic machinery in platelets, where loss of MLKL or its upstream regulator, RIPK3 kinase, impacted thrombosis and haemostasis. However, it remains unknown whether necroptosis operates within megakaryocytes, the progenitors of platelets, and whether necroptotic cell death might contribute to or diminish platelet production. Here, we demonstrate that megakaryocytes possess a functional necroptosis signalling cascade. Necroptosis activation leads to phosphorylation of MLKL, loss of viability and cell swelling. Analyses at steady state and post antibody-mediated thrombocytopenia revealed that platelet production was normal in the absence of MLKL, however, platelet activation and haemostasis were impaired with prolonged tail re-bleeding times. We conclude that MLKL plays a role in regulating platelet function and haemostasis and that necroptosis signalling in megakaryocytes is dispensable for platelet production.